Becton, Dickinson and Company (BD) has announced an investment exceeding $35m to expand the manufacturing of BD PosiFlush prefilled flush syringes at its facility in Columbus, Nebraska, US.
This expansion is expected to create around 50 new jobs and increase production capacity to meet the rising demand from US health systems and hospitals.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, prefilled flush syringes are essential in nearly every hospital for catheter care, helping to avoid complications and support patient safety.
The manufacturing quality of these syringes is paramount, as they deliver fluids directly into the bloodstream, where any contamination can lead to severe consequences.
The BD PosiFlush syringes are said to be produced using a hands-free and fully automated process to minimise contamination risks.
They feature a three-rib stopper tailored to minimise catheter reflux, a 10ml syringe barrel to reduce injection pressure risks, and a Luer-Lok Tip Cap to prevent contamination due to touch.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBD medication delivery solutions worldwide president Eric Borin said: “BD PosiFlush Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications.
“Our latest investments boost US production capacity and reinforce our commitment to a reliable supply for healthcare providers and the patients they serve.”
Over the past three years, the company made an investment of over $80m to increase the production of BD PosiFlush by more than 750 million units, with a 10% rise this year alone.
This investment is part of BD’s broader commitment to investing $2.5bn in US manufacturing over the next five-year period, which includes over $40m to widen needle, syringe, and IV catheter capacity.
Earlier this week, BD submitted an application to the FDA for an at-home human papillomavirus (HPV) test.
